Secondary Medical Prevention among Danish Patients Hospitalised with Either Peripheral Arterial Disease or Myocardial Infarction

European Journal of Vascular and Endovascular Surgery

Volumn 35, Issue 1, 2008, Pages 51-58

  Gasse, C ^a,b   Jacobsen, J ^a   Larsen, A C ^a,c   Schmidt, E B ^c   Johannesen, N L ^c   Videbaek J ^a   Sorensen H T ^a   Johnsen, S P ^a,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cohort study; Myocardial infarction; Peripheral arterial disease; Secondary medical prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTERY DISEASE; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DENMARK; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DENMARK; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOWER EXTREMITY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; POPULATION SURVEILLANCE; PRESCRIPTIONS, DRUG; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 37049018610     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2007.08.008     Document Type: Article

References (34)

1. Golomb B.A., Dang T.T., and Criqui M.H. Peripheral arterial disease: morbidity and mortality implications. Circulation 114 (2006) 688-699
2. McDermott M.M., Mehta S., Ahn H., and Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 12 (1997) 209-215
3. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European Society of Cardiology. American Heart Association. American College of Cardiology. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 173 (2004) 381-391 10.1016//j.atherosclerosis.2004.02.013
4. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G., and on behalf of the TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33 Suppl. 1 (2007) S1-S75 10.1016/j.ejvs.2006.09.024
5. Schroeder T.V., Ebskov L.B., Egeblad M., Husted S., Jelnes, Jensen T., et al. Underektremitetsiskæmi. Den almindelige Danske lægeforening. Konsensus report Nr. 2 (2005), Lægeforeningens forlag, København
6. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 113 (2006) e463-e654
7. Hirsch A.T., Criqui M.H., Treat-Jacobson D., Bakal C.W., Creager M.A., Halperin J.L., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1324
8. Burns P., Lima E., and Bradbury A.W. What constitutes best medical therapy for peripheral arterial disease?. Eur J Vasc Endovasc Surg 24 (2002) 6-12 10.1053/ejvs.2002.1684
9. McDermott M.M., Hahn E.A., Greenland P., Cella D., Ockene J.K., Brogan D., et al. Atherosklerotic risk factor reduction in peripheral arterial disease. J Gen Intern Med 17 (2002) 895-904
10. Lange S., Diehm C., Darius H., Haberl R., Allenberg J.R., Pittrow D., et al. High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. Exp Clin Endocrinol Diabetes 112 (2004) 566-573
11. Clark A.L., Byrne J.C., Nasser A., McGroarty E., and Kennedy J.A. Cholesterol in peripheral vascular disease-a suitable case for treatment?. QJM 92 (1999) 219-222
12. Bhatt D.L., Steg P.G., Ohman E.M., Hirsch A.T., Ikeda Y., Mas J.L., et al., REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189
13. Ness J., Aronow W.S., Newkirk E., and McDanel D. Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic. J Gerontol A Biol Sci Med Sci 60 (2005) 255-257
14. Bismuth J., Klitfod L., and Sillesen H. The lack of cardiovascular risk factor management in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg 21 (2001) 143-146 10.1053/ejvs.2000.1293
15. Eldrup N., and Sillesen H. Behandling af perifer karsygdom I almen praksis. Månedsskrift for praktisk lægegerning 82 (2004) 711-719
16. Nass C.M., Allen J.K., Jermyn R.M., and Fleisher L.A. Secondary prevention of coronary artery disease in patients undergoing elective surgery for peripheral arterial disease. Vasc Med 6 (2001) 35-41
17. Johnsen S.P., Larsson H., Tarone R.E., McLaughlin J.K., Norgard B., Friis S., et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 165 (2005) 978-984
18. Frank L. Epidemiology. When an entire country is a cohort. Science 287 (2000) 2398-2399
19. Andersen T.F., Madsen M., Jorgensen J., Mellemkjoer L., and Olsen J.H. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46 (1999) 263-268
20. Gaist D., Sorensen H.T., and Hallas J. The Danish prescription registries. Dan Med Bull 44 (1997) 445-448
21. The WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/.
22. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
23. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
24. Sillesen H. Who should treat patients with peripheral arterial disease - the vascular specialist. Eur J Vasc Endovasc Surg 24 (2002) 1-3 10.1053/ejvs.2002
25. Second European Consensus Document on Chronic Critical leg Ischaemia. Circulation 84 Suppl. 4 (1991)
26. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., and Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 19 (1998) 1434-1503
27. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg 19 Suppl. A (2000) S1-250 Si-xxviii
28. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
29. Hiatt W.R. Pharmacologic therapy for peripheral arterial disease and claudication. J Vasc Surg 36 (2002) 1283-1291
30. Willigendael E.M., Teijink J.A., Bartelink M.L., Boiten J., Moll F.L., Buller H.R., et al. Peripheral arterial disease: public and patient awareness in The Netherlands. Eur J Vasc Endovasc Surg 27 (2004) 622-628 10.1016/j.ejvs.2004.02.019
31. Adam D.J., and Bradbury A.W. TASC II document on the management of peripheral arterial disease. Eur J Vasc Endovasc Surg 33 (2007) 1-2 10.1016/j.ejvs.2006.11.008
32. Hirsch A.T., Gloviczki P., Drooz A., Lovell M., Creager M.A., and Board of Directors of the Vascular Disease Foundation. Special communication: mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health. Angiology 55 (2004) 233-242
33. Sillesen H., Madelung S., Eldrup N., and Roed M. Organising a Nurse-driven PAD Rehabilitation Clinic Within the Vascular Surgical Department: what is Required and are Treatment Goals Reached - A Prospective Study?. Eur J Vasc Endovasc Surg 33 (2007) 26-32 10.1016/j.ejvs.2006.07.022
34. Madsen M., Davidsen M., Rasmussen S., Abildstrom S.Z., and Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 56 (2003) 124-130 10.1016/S0895-4356(02)00591-7